Edward Mackey - Boston Scientific Executive Vice President - Global Operations
| BSX Stock | USD 89.25 0.75 0.83% |
President
Mr. Edward F. Mackey is Executive Vice President Operations of the Company. In this role, he is responsible for Global Manufacturing and Supply Chain, Quality and Regulatory Affairs, Information Technology, Global Business Services, Global Business Excellence, Corporationrationrate Research and Development, and Corporationrationrate Marketing and Market Access. Prior to joining Boston Scientific, Mr. Mackey was worldwide president of DePuy Synthes Power Tools, a division of Johnson Johnson from November 2012 to January 2015, and vice president of Integration for Johnson Johnson acquisition of Synthes from June 2010 to November 2012. Early in his career, Mr. Mackey held management positions in Operations, Quality and Product Development at Raytheon Mille Systems division. In 1995, he moved to Johnson Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles, becoming worldwide vice president of Supply Chain and Manufacturing for DePuy since 2015.
| Age | 58 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.049 % which means that on every $100 spent on assets, it made $0.049 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0892 %, implying that it generated $0.0892 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.14 in 2024, whereas Return On Equity is likely to drop 0.06 in 2024. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 30.1 B in 2024, whereas Other Current Assets are likely to drop slightly above 544.2 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Yin Becker | Stryker | 57 | |
| Daniel Salvadori | Abbott Laboratories | 45 | |
| Suketu Upadhyay | Zimmer Biomet Holdings | 55 | |
| Ellison Humphrey | Zimmer Biomet Holdings | N/A | |
| Bradley Lerman | Medtronic PLC | 63 | |
| Roger Bird | Abbott Laboratories | 63 | |
| Mark Gladwell | Smith Nephew SNATS | 44 | |
| Karen Burton | STERIS plc | 56 | |
| Vasant Padmanabhan | Smith Nephew SNATS | 57 | |
| Daniel Carestio | STERIS plc | 51 | |
| Richard Kuntz | Medtronic PLC | 63 | |
| Catherine Szyman | Edwards Lifesciences Corp | 54 | |
| Skip Kiil | Smith Nephew SNATS | 45 | |
| Geoffrey Martha | Medtronic PLC | 54 | |
| Hubert Allen | Abbott Laboratories | 58 | |
| Brent Ladd | Stryker | N/A | |
| Maurice BenMayor | Stryker | N/A | |
| Andrew Lane | Abbott Laboratories | 49 | |
| Frank Chan | Medtronic PLC | N/A | |
| Donald Payerle | Stryker | N/A | |
| Robert Hoedt | Medtronic PLC | 64 | |
Management Performance
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Nelda Connors, Independent Director | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Daniel CPA, Executive CFO | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Jeffrey MBA, Executive Interventions | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 141.4 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 92.48 % | ||||
| Number Of Shares Shorted | 12.91 M | ||||
| Price To Earning | 107.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.